Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial
ContributorsNatalucci, Giancarlo; Latal, Beatrice; Koller, Brigitte Marie; Ruegger, Christoph Emanuel; Sick, Beate; Held, Leonhard; Bucher, Hans Ulrich; Fauchère, Jean-Claude; Pfister, Riccardo; The Swiss EPO Neuroprotection Trial Group
Published inJAMA (Journal of the American Medical Association), vol. 315, no. 19, p. 2079-2085
Publication date2016
Abstract
Keywords
- Child Development
- Child, Preschool
- Developmental Disabilities/prevention & control
- Double-Blind Method
- Drug Administration Schedule
- Erythropoietin/administration & dosage
- Female
- Humans
- Infant, Newborn
- Infant, Premature
- Intention to Treat Analysis
- Male
- Neurodevelopmental Disorders/prevention & control
- Neuroprotective Agents/administration & dosage
- Recombinant Proteins/administration & dosage
- Treatment Outcome
Affiliation entities
Citation (ISO format)
NATALUCCI, Giancarlo et al. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. In: JAMA (Journal of the American Medical Association), 2016, vol. 315, n° 19, p. 2079–2085. doi: 10.1001/jama.2016.5504
Main files (1)
Article (Published version)
Identifiers
- PID : unige:97117
- DOI : 10.1001/jama.2016.5504
- PMID : 27187300
Journal ISSN0098-7484
